Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Nov 19, 2021 1:56pm
155 Views
Post# 34146856

RE:RE:RE:RE:RE:RE:RE:RE:hyping TH

RE:RE:RE:RE:RE:RE:RE:RE:hyping THThat job posting was removed while ago not sure when but quite while ago. I would think by now they had completed the interview process. Not all their employees are listed on LinkedIn last time I check I couldn't find anyone with that job title. If I remember correctly there is a lady in charge of communication and events maybe that's the new communication manager!
SPCEO1 wrote: So it appears they are deep into the interview process but have not hired anyone yet - is that your understanding too (not taking anymore applications but the position is still open).

scarlet1967 wrote: I think this was the person you are referring to.
Check out this job at Theratechnologies Inc.: Communications Manager
https://www.linkedin.com/jobs/view/2634295872

Wino115 wrote: I thought they had hired someone for PR before he had left, sort of took that away from him first. I could be wrong but there was a job rec out there for that and I thought someone said the position was hired.
SPCEO1 wrote: Did TH announce they had filled Boucher's post? Or had you heard that somewhere else?

Wino115 wrote: I learned that newscasts in Quebec are as unsophisticated as they are here in the US. You can't really expect Mssr. Zappo to know much of anything beyond what kind of hair gel holds up his coif. There are some serious-minded science newscasters around but I'm guessing he isn't one. My guess is this is the first "coup" the new Communications and PR person got them. It's more than what Boucher did in years. Not very sophisticated, but I applaud them at least getting out to talk about their platform. If one out of 5 of their PR/Communication's outreach is a fluff piece like this, fine. But you need to get the other 4 serious science or investment oriented PR opportunities.
jfm1330 wrote: Sentiments of the host will not pan out because they are based on ignorance. I don't know who gave him the idea of a cure for cancer, but it makes no sense. The host in the labs with Beliveau looked like a little boy in a candy store, very impressed by all the sophisticated instruments and with a well known scientist in Quebec that was very enthusiatic. I understand the enthusiasm of Beliveau, this whole thing comes out of his lab. He is proud of it, but I think something went wrong in the messaging. At he same time, there was Levesque also there, very corporate, talking about the reaction of American investors to the science and the preclinical data, as if he was unaware of what is going on with the phase Ia. But again, just the fact that they agreed to such a TV report on their cancer therapy at this time is positive. Why would you expose yourself like that on the specific topic of oncology when you are well into the phase Ia?

SPCEO1 wrote: To be fair, Paul has been hyping it in any presentation he has made with his significant use of many and somewhat varied superlatives. Unfortunately, the forum for this hyping is still not all that consequential for the stock. The reaction of the stock to the recommendation to buy the stock on Fox Business channel was much more impactful, if only for a short while. They need to have a very good plan to promote their Sort1+ platform if the sentiments revealed on that program, admttedly maybe mostly by the host, pan out., 

princess77 wrote: Finally TH being talked up by the company, I appreciate it. I don't see any false hope being given in that article. They are excited, finally.
 

 

 

 

 

 

 




<< Previous
Bullboard Posts
Next >>